SALMONELLA

VolverVolver

Resultados 69 resultados LastUpdate Última actualización 15/09/2019 [19:51:00] pdf PDF

Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days

Página1 de 3 nextPage   por página


Methods for Detecting Microorganisms Using Microorganism Detection Protein and Other Applications of Cell Binding Components

NºPublicación: US2019276868A1 12/09/2019

Solicitante:

LABORATORY CORP AMERICA HOLDINGS [US]

Resumen de: US2019276868A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

traducir

USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER

NºPublicación: US2019275128A1 12/09/2019

Solicitante:

CLEVELAND BIOLABS INC [US]

US_2018344823_A1

Resumen de: US2019275128A1

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

traducir

METHODS FOR DETECTING MICROORGANISMS USING MICROORGANISM DETECTION PROTEIN AND OTHER APPLICATIONS OF CELL BINDING COMPONENTS

NºPublicación: WO2019173838A1 12/09/2019

Solicitante:

LABORATORY CORP AMERICA HOLDINGS [US]
ERICKSON STEPHEN [US]
GIL JOSE S [US]
NGUYEN MINH MINDY BAO [US]
ANDERSON DWIGHT L [US]
HAHN WENDY [US]
PAULSON JOHN [US]

US_2019276868_A1

Resumen de: WO2019173838A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

traducir

IMMUNOGENIC CONJUGATES AND USE THEREOF

NºPublicación: CN110214022A 06/09/2019

Solicitante:

\u845B\u5170\u7D20\u53F2\u5BC6\u4E1D\u514B\u83B1\u6069\u751F\u7269\u6709\u9650\u516C\u53F8

CA_3044569_A1

Resumen de: WO2018096007A2

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

traducir

肠炎沙门菌glpK基因缺失的应用

NºPublicación: CN110205277A 06/09/2019

Solicitante:

\u6CB3\u5317\u79D1\u6280\u5E08\u8303\u5B66\u9662

Resumen de: CN110205277A

本发明公开了一种肠炎沙门菌glpK基因缺失的应用,利用λ‑Red重组技术构建肠炎沙门菌glpK基因缺失株,并对其生物学特性和毒力进行研究,明确了glpK基因缺失引起肠炎沙门菌毒力下降,为设计肠炎沙门菌疫苗靶点提供参考,进而防治肠炎沙门菌感染。

traducir

SYNTHETIC BACTERIOPHAGES AND BACTERIOPHAGE COMPOSITIONS

NºPublicación: EP3532850A1 04/09/2019

Solicitante:

MASSACHUSETTS INST TECHNOLOGY [US]

US_2018155721_A1

Resumen de: WO2018081502A1

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

traducir

Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prohylactic use or treatment of salmonella infection

NºPublicación: NZ742089A 30/08/2019

Solicitante:

AXICHEM AB

US_2019059417_A1

Resumen de: NZ742089A

The invention relates to bird feed comprising synthetic capsaicinoids for prohylactic use of the general formula for treatment of salmonella infection.

traducir

NOVEL SALMONELLA HEIDELBERG BACTERIOPHAGE SAL-HEP-1 AND USE THEREOF FOR INHIBITING GROWTH OF SALMONELLA HEIDELBERG BACTERIA

NºPublicación: WO2019164194A1 29/08/2019

Solicitante:

INTRON BIOTECHNOLOGY INC [KR]

KR_20190100663_A

Resumen de: WO2019164194A1

The present invention relates to: a Podoviridae bacteriophage Sal-HEP-1 (accession number: KCTC 13454BP) isolated from nature, the Podoviridae bacteriophage Sal-HEP-1 having the ability to kill Salmonella Heidelberg bacteria and having a genome represented by SEQ ID NO: 1; and a method for preventing and treating diseases induced by the Salmonella Heidelberg bacteria by using a composition containing the Podoviridae bacteriophage Sal-HEP-1 as an active ingredient.

traducir

NOVEL SALMONELLA HEIDELBERG BACTERIOPHAGE SAL-HEP-1 AND USE THEREOF FOR INHIBITING GROWTH OF SALMONELLA HEIDELBERG BACTERIA

NºPublicación: KR20190100663A 29/08/2019

Solicitante:

INTRON BIOTECHNOLOGY CO LTD [KR]

WO_2019164194_A1

Resumen de: WO2019164194A1

The present invention relates to: a Podoviridae bacteriophage Sal-HEP-1 (accession number: KCTC 13454BP) isolated from nature, the Podoviridae bacteriophage Sal-HEP-1 having the ability to kill Salmonella Heidelberg bacteria and having a genome represented by SEQ ID NO: 1; and a method for preventing and treating diseases induced by the Salmonella Heidelberg bacteria by using a composition containing the Podoviridae bacteriophage Sal-HEP-1 as an active ingredient.

traducir

Combined Lysis Protocol for Comprehensive Cell Lysis

NºPublicación: KR20190100315A 28/08/2019

Solicitante:

SHORELINE BIOME LLC [US]

AU_2017388204_A1

Resumen de: US2018187181A1

Disclosed are methods for lysis of cells, such as bacteria present in microbiomes, that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allows for simplified removal of detergent after lysis, and importantly, yields improved quantities of genomic DNA (gDNA) from difficult to lyse bacteria.

traducir

AUTOMATED PRIMING AND LIBRARY LOADING SERVICES

NºPublicación: SG11201903333SA 27/08/2019

Solicitante:

CLEAR LABS INC [US]

AU_2018353924_A1

Resumen de: SG11201903333SA

ScreeningRisk Assessment Low Risk High Risk Quality Measures Reported 0 Shelf-life & Freshness (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 July 2019 (04.07.2019) WIPO I PCT 11111111111111011111111111111110111110101111111111111111111111111111111111111011110111111 (10) International Publication Number WO 2019/133756 Al (51) International Patent Classification: BO1J 19/00 (2006.01) Cl 2N 15/09 (2006.01) C12N 9/00 (2006.01) Cl 2P 19/34 (2006.01) C12N 9/10 (2006.01) Cl 2Q 1/68 (2018.01) C12N 9/16 (2006.01) (21) International Application Number: PCT/US2018/067750 (22) International Filing Date: 27 December 2018 (27.12.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/611,846 29 December 2017 (29.12.2017) US 62/646,135 21 March 2018 (21.03.2018) US 62/730,288 12 September 2018 (12.09.2018) US (71) Applicant: CLEAR LABS, INC. [US/US]; 3565 Haven Avenue, Suite 2, Menlo Park, California 94025 (US). (72) Inventors: AMINI, Sasan; 626 Poplar Avenue, Redwood City, California 94061 (US). KHAKSAR, Ramin; 131 Santa Clara Avenue, Redwood City, California 94061 (US). TAYLOR, Michael; 10805 Torrance Drive, Kens- ington, Maryland 20895 (US). SHOKRALLA, Shadi; 716 Westbrook Ct., Danville, California 94506 (US). HANEY, Christopher; 100 N Whisman Rd., #1313, Mountain View, California 94043 (US). VAIDYANATHAN, Pava

traducir

一种O抗原亲和介质及其制备方法和应用

NºPublicación: CN110172087A 27/08/2019

Solicitante:

\u4E2D\u56FD\u79D1\u5B66\u9662\u8FC7\u7A0B\u5DE5\u7A0B\u7814\u7A76\u6240

Resumen de: CN110172087A

本发明提供了一种O抗原亲和介质及其制备方法和应用,所述O抗原亲和介质包括超大孔介质和沙门氏菌的O抗原,所述O抗原化学固定在超大孔介质表面。本发明的O抗原亲和基质制备过程简单,纯化操作简便,效率高,利用该亲和介质和纯化方法制备出的抗体对O抗原具有高特异性,可用于辅助沙门氏菌诊断等应用。

traducir

NATURAL MICROORGANISMS WHICH ARE NATURALLY CAPABLE OF BINDING TOXINS AND/OR TOXIN RECEPTORS

NºPublicación: US2019257832A1 22/08/2019

Solicitante:

ULSEMER PHILIPPE [DE]
GOLETZ STEFFEN [DE]
GOETZ PETER [DE]

WO_2018015380_A1

Resumen de: US2019257832A1

The present invention relates to means and method for isolating naturally-occurring microorganisms (non-pathogenic bacteria, yeasts or fungi) capable of binding toxins from microorganisms such as bacteria, viruses, fungi, yeasts, or protozoans and/or receptors for these toxins on the surface of mammalian cells, thereby making these receptors inaccessible for said toxins. The naturally-occurring microorganisms that are obtainable by the means and methods of the present invention can be used for adsorbing toxins from pathogenic microorganisms and/or blocking receptors for such toxins on the surface of mammalian cells. These toxin-receptor interactions are known to be critical for disease pathogenesis, making both the toxins and receptors a target for the naturally-occurring microorganisms of the present invention.

traducir

Induction of protective immunity against antigens

NºPublicación: AU2018210554A1 22/08/2019

Solicitante:

UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED

CA_3050724_A1

Resumen de: AU2018210554A1

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

traducir

EXTRACT OF AN HERBAL COMPOSITION AS ANTIMICROBIAL AND/OR ANTIBIOFILM AGENT

NºPublicación: US2019255136A1 22/08/2019

Solicitante:

ALPHANOSOS S A S [FR]

Resumen de: US2019255136A1

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

traducir

MHC class I epitope delivering polypeptides

NºPublicación: AU2019210656A1 22/08/2019

Solicitante:

MOLECULAR TEMPLATES INC

AU_2019204364_A1

Resumen de: AU2019210656A1

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD 8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin- derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. 5 The present invention provides cell-targeted, CDS+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capabl e of delivering one or more 10 heterologous T- cell epitopes to the MHC class I presentation pathway, including polypeptides which are I ) B- cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

traducir

A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT

NºPublicación: EP3526340A1 21/08/2019

Solicitante:

GENETIC ANALYSIS AS [NO]

CN_110114471_A

Resumen de: WO2018069538A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

traducir

High Sensitivity Impedance Sensor

NºPublicación: US2019250159A1 15/08/2019

Solicitante:

UNIV MISSOURI [US]

US_2016299138_PA

Resumen de: US2019250159A1

Disclosed herein are example embodiments of a transformative sensor apparatus that is capable of detecting and quantifying the presence of a substance of interest such as a specified bacteria within a sample via changes in impedance exhibited by a detection electrode array. In an example embodiment, sensitivity is improved by including a focusing electrode array in a rampdown channel to focus a concentration of the substance of interest into a detection region. The focusing electrodes include an opposing pair of electrodes in a rampdown orientation. The focusing electrode may also include tilted thin film finger electrodes extending from the rampdown electrodes. In another example embodiment, trapping electrodes are positioned to trap a concentration of the substance of interest onto the detection electrode array.

traducir

BROAD SPECTRUM SALMONELLA PHAGE AND APPLICATION THEREOF

NºPublicación: WO2019154032A1 15/08/2019

Solicitante:

QINGDAO PHAGEPHARM BIO TECH CO LTD [CN]

CN_108359644_A

Resumen de: WO2019154032A1

Provided is a salmonella phage, particularly relating to a long-tail broad host spectrum salmonella pullorum strong lytic phage. Said salmonella pullorum phage is named SP4, being collected in the China General Microbiological Culture Collection Centre, the collection date being 27 July 2017, and the collection number being CGMCC No. 14332. The phage has a strong lytic effect on salmonella, and the phage can also reduce the mortality of chicks infected with pullorosis. The preparation can be used individually or in a cocktail to provide a safe, non-toxic, and non-residual action phage product source for the treatment of salmonella infections from poultry, ducks, mink, food sources, and pigs.

traducir

IMMUNOMODULATOR FOR HYPERSENSITIVITY REACTION TO HOUSE DUST MITE-DERIVED ALLERGEN

NºPublicación: US2019247465A1 15/08/2019

Solicitante:

MD HEALTCHARE INC [KR]

JP_2019501926_A

Resumen de: US2019247465A1

The present invention relates to an immunomodulator for the prevention or treatment of an allergic disease caused by house dust mite-derived allergens. Particularly, the present invention provides an immunomodulatory pharmaceutical composition comprising as an effective ingredient a bacteria extracellular vesicle containing an allergens derived from North American house dust mite or European house dust mite, and a preparation method therefor.

traducir

Bacteriocins for control of Salmonella enterica

NºPublicación: AU2018239310A1 15/08/2019

Solicitante:

NOMAD BIOSCIENCE GMBH

CA_3052109_A1

Resumen de: AU2018239310A1

The present invention relates to bacteriocins for control of

traducir

FORMULATION OF BANANA PSEUDOSTEM LIQUID EXTRACT AND ITS USES

NºPublicación: PH12018000039A1 14/08/2019

Solicitante:

MARTE BENJAMIN REUEL G [PH]

Resumen de: PH12018000039A1

The invention describes banana pseudostem-based liquid extracts and its applications as an antimicrobial against Escherichia coli, Salmonella typhimurium, and Staphylococcus aureus, and as a quorum sensing inhibition agent against Pseudomonas aeruginosa. The formulations are either in ethanolic or aqueous forms. The extracts were tested against Escherichia coli, Salmonella typhimurium, Staphylococcus aureus via disc diffusion method; and Pseudomonas aeruginosa via agar diffusion assay and the zones of inhibition were observed. Results include and antibacterial and quorum sensing inhibition activity in the extracts, especially in the autoclaved aqueous forms.

traducir

BACTERIAL MINICELLS FOR DELIVERING NUCLEIC ACID ADJUVANTS AND METHODS OF USING THE SAME

NºPublicación: EP3522935A1 14/08/2019

Solicitante:

ENGENEIC MOLECULAR DELIVERY PTY LTD [AU]

CN_110022905_A

Resumen de: US2018100159A1

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.

traducir

PROTEIN MATRIX VACCINE COMPOSITIONS INCLUDING POLYCATIONS

NºPublicación: EP3524265A1 14/08/2019

Solicitante:

MATRIVAX INC [MC]

CN_103747798_A

Resumen de: EP3524265A1

The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.

traducir

A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT

Nº publicación: CN110114471A 09/08/2019

Solicitante:

\u9057\u4F20\u5206\u6790\u80A1\u4EFD\u6709\u9650\u516C\u53F8

AU_2017342088_A1

Resumen de: WO2018069538A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

traducir

Página1 de 3 nextPage por página

punteroimgVolver